Literature DB >> 4656355

Experimental oral immunization with L-forms of Vibrio cholerae.

S C Agarwal, N K Ganguly.   

Abstract

It has been found that oral administration of lysates of L-forms of Vibrio cholerae are antigenic and capable of eliciting an early and high coproantibody response. The L-forms of V. cholerae did not produce any booster effect. Coproantibody rise persists to significant levels even six weeks after oral immunization. L-form lysates of V. cholerae also produce a considerable rise of circulating antibodies and these persist in significantly high titers up to six weeks.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4656355      PMCID: PMC422316          DOI: 10.1128/iai.5.1.31-34.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  ORAL IMMUNIZATION AND PRODUCTION OF COPROANTIBODY IN HUMAN VOLUNTEERS.

Authors:  R FRETER; E J GANGAROSA
Journal:  J Immunol       Date:  1963-12       Impact factor: 5.422

2.  The importance of antibody in the prevention of experimental cholera in rabbits.

Authors:  C R JENKIN; D ROWLEY
Journal:  Br J Exp Pathol       Date:  1960-02

3.  Quantitative studies of the relationship between fecal and serum antibody.

Authors:  M E KOSHLAND; W BURROWS
Journal:  J Immunol       Date:  1950-07       Impact factor: 5.422

4.  Vibriocidal activity, immune globulin producing cells and immune globulin levels in Theropithecus gelada after administration of a vibrio cholerae antigen.

Authors:  O Felsenfeld; W E Greer
Journal:  Immunology       Date:  1968-03       Impact factor: 7.397

5.  Agglutinin and vibriocidal responses of L forms of Vibrio cholerae and El tor.

Authors:  S C Agarwal; N K Ganguly
Journal:  Indian J Med Res       Date:  1971-06       Impact factor: 2.375

6.  Live oral cholera vaccine: report of a trial on human volunteer subjects.

Authors:  S C Sanyal; S Mukerjee
Journal:  Bull World Health Organ       Date:  1969-04       Impact factor: 9.408

7.  Production of antitoxic immunity by live oral cholera vaccine.

Authors:  P Bhattacharya; A Narayanaswami; S Mukerjee
Journal:  J Bacteriol       Date:  1968-01       Impact factor: 3.490

8.  Further studies on the development of a live oral cholera vaccine.

Authors:  P Bhattacharya; S Mukerjee
Journal:  J Hyg (Lond)       Date:  1968-06

9.  Coproantibody and bacterial antagonism as protective factors in experimental enteric cholera.

Authors:  R FRETER
Journal:  J Exp Med       Date:  1956-09-01       Impact factor: 14.307

10.  Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. I. The virus carrier state and the development of neutralizing antibodies.

Authors:  J L MELNICK; A S KAPLAN
Journal:  J Exp Med       Date:  1953-03       Impact factor: 14.307

  10 in total
  5 in total

Review 1.  Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells.

Authors:  K L Richards; S D Douglas
Journal:  Microbiol Rev       Date:  1978-09

2.  Comparison of quantitative and qualitative antibody-producing cell responses to lipopolysaccharide in cell walls of the bacterial form and in membranes of the protoplast L-form of Proteus mirabilis.

Authors:  H Karch; K Nixdorff
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

3.  Cell-mediated immunity after oral immunization with ribonucleic acid-protein fractions of Vibrio cholerae L-form lysates.

Authors:  S C Agarwal; T Sundararaj
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

4.  Cell-mediated immunity to Vibrio cholerae with ribonucleic acid-protein fractions of V. cholerae L-form lysates.

Authors:  S C Agarwal; T Sundararaj
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

5.  Oral immunization with L-forms of Vibrio cholerae in human volunteers.

Authors:  S C Agarwal; N K Ganguly
Journal:  Infect Immun       Date:  1972-07       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.